





# Spotlight on Rare Cancers: Advancing Novel Therapy and Patient Centered Management At-a-Glance Update, Sessions 5-9

Live-Virtual CME Activities launched 11/12/2020 • On Demand through 10/28/2021  
Reporting data as of 12/14/2020

## Learners To Date



5  
patients seen per week (aggregated across all sessions and conditions)


Which translates to

1,280


Patient Visits/week  
66,560/year

\*Target Audience: Hematology, Oncology, Hematologic Oncologists, Pathology, Radiologic Oncologists, Surgical Oncologists, Primary Care


## Learners by Degree (%)




## Learners by Specialty (%)




## US Learners by Region



## Engagement



## Post-Education Anticipated Change



n=167, program evaluation

Knowing how to discuss education and other factors that improve shared decision making.

Refer patients for rare disease information and advocacy groups.

Broaden my understanding of these conditions and heighten my awareness.

Better understanding of pathways involved.

More specifically look out for targetable mutations.

Take information to get my team ready for new treatment options, support group initiation for our team as needed.

Better diagnosing and treating all types of soft tissue sarcoma.

Learner examples shared of knowledge improvement & anticipated practice changes

This activity is supported by educational grants from Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, LLC.; Eisai Inc.; Epizyme Inc.; Innate Pharma, Inc.; Ipsen Biopharmaceuticals, Inc.; Karyopharm Therapeutics; Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.

Terms used in this report align with definitions in the Outcomes Standardization Project Glossary (outcomesinc.org)